EVENTS | VIEW CALENDAR
QIAGEN to create NGS portfolio for clinical research, MDx
HILDEN, GermanyŚQIAGEN NV recently unveiled an initiative to enter the field of next-generation sequencing (NGS) with the aim to establish these technologies as routine processes used in new areas such as clinical research and molecular diagnostics.
The company said it is "in the advanced stages of creating sample-to-result, efficient and cost-effective NGS workflow solutions." These will combine a broad range of QIAGEN products, including automated sample preparation solutions (nucleic acid extraction, DNA enrichment, library preparation and targeted gene analysis panels), with a previously undisclosed next- generation benchtop sequencer in development with Intelligent Bio-Systems Inc., a privately held company that QIAGEN has acquired. New bioinformatics, including solutions emerging from a new collaboration with SAP AG, will be incorporated into the workflows.
The first NGS solution is expected to be launched next year, while details on specifications and launch plans will be released in early 2013.
"The rapid advances in next-generation sequencing have enabled life-science researchers to unlock many secrets about the molecular building blocks of life. Our ambition is to create a new dimension of benefits for these technologies by offering workflow solutions for clinical use, particularly to develop new medicines and improve healthcare with advanced diagnostics," said Peer M. Schatz, CEO of QIAGEN, in a press release. "While next-generation sequencing is viewed today mainly as a research tool, our initiative is to expand beyond this and to offer applications designed to address the needs of customers in clinical research and molecular diagnostics."
QIAGEN said it anticipates these technologies to be dilutive to adjusted earnings per share by approximately 1 cent for full-year results in 2012 and by approximately 2 cents in 2013, but accretive to full-year results in 2014.